Intestinal disease | FIV | Magazine https://fivmagazine.com Sat, 16 May 2026 13:37:08 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.5 Cannabis for Crohn’s disease: CBD, remission & studies https://fivmagazine.com/cannabis-for-crohns-disease-cbd-remission-studies/ https://fivmagazine.com/cannabis-for-crohns-disease-cbd-remission-studies/#respond Sun, 05 Apr 2026 16:00:00 +0000 https://fivmagazine.de/cannabis-for-crohns-disease-cbd-remission-studies/ Most important: Naftali 2013 – the first RCT on cannabis in Crohn’s disease – showed 45% full remission with THC cannabis versus 10% placebo. CBD alone was not sufficient for remission induction. THC component is crucial for Crohn’s disease.
At a glance:

  • Naftali 2013 (RCT): 45 % full remission with cannabis vs. 10 % placebo in Crohn’s disease
  • CBD alone is not enough – the THC component is crucial for remission induction
  • CBD inhibits CYP3A4 → Interaction with azathioprine and infliximab – medical coordination necessary

Crohn’s disease and the endocannabinoid system

Crohn’s disease is a chronic inflammatory bowel disease (IBD) that can affect any part of the digestive tract and is characterized by relapses of varying intensity. The endocannabinoid system is deeply integrated into intestinal homeostasis: CB1 and CB2 are found on intestinal epithelium, intestinal immune cells, enteric neurons and intestinal smooth muscle.

ECS and gut physiology: where cannabis comes in

ECS function in the intestine receptor Cannabis effect
Intestinal motility CB1 on enteric neurons THC: reduces hypermotility (less diarrhea, cramps)
Intestinal permeability (leaky gut) CB1 on epithelial cells CBD + THC: strengthen tight junction proteins
Intestinal immune response CB2 on macrophages, mast cells CB2 activation: less TNF-α, IL-1β, IL-6
Pain modulation CB1 in pain neurons THC + CBD: central and peripheral analgesia
Visceral hypersensitivity TRPV1 on intestinal neurons CBD desensitizes TRPV1 → less pain

Key studies: Cannabis and Crohn’s disease

Naftali et al. 2013 (Clin Gastroenterol Hepatol): First prospective RCT on cannabis in Crohn’s disease. n=21, cannabis vs. placebo (tobacco-placebo). Cannabis group (115 mg THC/day via joints): 45 % full remission vs. 10 % placebo. Statistically significant. But: small number of cases, blinding problematic due to obvious effect.

Naftali et al. 2017 (Pharmacology): Follow-up with CBD oil specifically. CBD alone without THC: no significant improvement in disease activity (CDAI score). Conclusion: THC component more important for remission induction than CBD.

Irving et al. 2018 (J Crohns Colitis): RCT, n=60, cannabidiol in ulcerative colitis. CBD showed no significant superiority over placebo on clinical remission. But: quality of life and some inflammatory parameters improved.

Conclusion: THC in active Crohn’s disease shows clinical remission potential. CBD alone is not sufficient for remission induction, but can improve quality of life and pain.

Practical application: cannabis for Crohn’s disease

Acute attack (pain relief):
– THC 5-10 mg via vaporizer (immediate onset of action, intestinal motility ↓, analgesia)
– CBD 50-100 mg sublingual (anti-inflammatory, TRPV1 desensitization)

Maintenance of remission (daily intake):
– CBD 50-100 mg daily (anti-inflammatory, intestinal permeability)
– Full spectrum preferred for entourage effect (Naftali 2013: THC full spectrum more effective than CBD alone)

Sleep disorders in Crohn’s disease:
– CBD 150 mg + THC 5 mg in the evening

Augmentation problem with Crohn’s immunosuppressants

Crohn’s patients often receive immunosuppressants (azathioprine, infliximab). CBD inhibits CYP3A4 and CYP2D6 – relevant enzymes for the metabolism of these drugs. In case of combination: medical consultation mandatory due to interaction potential.

Study highlight: Naftali 2013 (RCT, n=21): 45 % full remission in active Crohn’s disease with cannabis flowers (115 mg THC/day). Placebo: 10 %. CB1 and CB2 on intestinal immune cells and intestinal epithelium are the pharmacological basis – directly at the source of inflammation.

FAQ: Cannabis for Crohn’s disease

Summary

ECS is deeply integrated into intestinal physiology: CB1 on motility and permeability, CB2 on intestinal immune response. Naftali 2013 shows 45% Crohn’s remission with THC cannabis. CBD alone weaker for remission induction, but valuable for pain and quality of life. Full spectrum preferred. Check drug interactions with immunosuppressant combination. Cannabis and immune system for CB2 mechanisms; cannabis in irritable bowel synd rome for related bowel diseases.

Cannabis prescription online? Our teleclinic comparison shows all 31 providers in direct comparison – with prices, waiting times and real reviews. Free and independent.
]]> https://fivmagazine.com/cannabis-for-crohns-disease-cbd-remission-studies/feed/ 0